Genmab (Otc) ((GMAB)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Study Overview: Genmab is conducting a clinical trial titled First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. The study aims to assess the safety and optimal dosing of acasunlimab, an antibody treatment, in patients with malignant solid tumors. This research is significant as it explores new therapeutic options for cancer treatment.
Intervention/Treatment: The trial tests acasunlimab, both as a standalone treatment and in combination with docetaxel or pembrolizumab, with or without chemotherapy. These interventions aim to evaluate the efficacy of acasunlimab in treating various cancers.
Study Design: This interventional study follows a sequential model without masking, focusing on treatment as its primary purpose. The study is divided into two parts: dose escalation and expansion, to determine the safety and efficacy of acasunlimab.
Study Timeline: The trial began on May 14, 2019, with an active status but not recruiting. The last update was submitted on August 4, 2025. These dates are crucial for tracking the study’s progress and anticipated outcomes.
Market Implications: This update could positively influence Genmab’s stock performance by demonstrating progress in developing innovative cancer treatments. The study’s results may affect investor sentiment, especially if acasunlimab shows promising efficacy, potentially positioning Genmab competitively within the biotech industry.
The study is ongoing, with further details available on the ClinicalTrials portal.